Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05288179RecruitingPhase 3
Pirfenidone capsules for silicosis or coal dust lung disease
This Phase 3 trial tests whether pirfenidone slows or improves lung damage in people with silicosis or coal worker’s pneumoconiosis. It looks at both effectiveness and side effects, and uses lung function tests and lung scans to track changes over time.
BeijingAges 18–70 - NCT05306899RecruitingPhase 3
IV ketamine for chronic daily headaches
This trial tests whether an IV dose of ketamine can reduce chronic daily headaches and is safe for people with this condition. It may help by lowering headache frequency and severity, but it also has several medicine and health-related safety checks.
Toronto, OntarioAges 18–75 - NCT05314738RecruitingPhase 1/Phase 2
Corneal cross-linking trial for keratoconus eye
This trial tests how safe and effective corneal cross-linking is for people with keratoconus, a condition that changes the shape of the clear front surface of the eye. If you qualify, the study will also require several follow-up visits to check your eye health over time.
Dothan, AlabamaAges 18–55 - NCT05338190RecruitingPhase 3
Belimumab added to rituximab for chronic immune thrombocytopenia
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
CréteilAges 18 years+ - NCT05343325RecruitingPhase 2
Neoadjuvant low-dose radiation with chemo-immunotherapy for head and neck cancer
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
Zhuhai, GuangdongAges 18–70 - NCT05344209RecruitingPhase 2
Pembrolizumab plus or minus vaccine for advanced lung cancer
This Phase 2 trial studies pembrolizumab (an immune-boosting cancer medicine) alone or with an added investigational UV1 vaccine in people with advanced non-small cell lung cancer. It aims to see whether adding the vaccine improves safety and effectiveness, especially in tumors with high PD-L1 levels.
Drammen, AkershusAges 18 years+ - NCT05347069RecruitingPhase 4
Aspirin study for people with stable heart artery disease
This trial tests whether daily aspirin is safe and effective for people who have stable (chronic) coronary artery disease but cannot have procedures to open blocked arteries. It may help reduce future heart problems, while also checking for side effects and risks from aspirin.
KyotoAges 20 years+ - NCT05351502RecruitingPhase 1
Nitric oxide injection for solid tumors that can’t be removed
This Phase 1 study tests whether injecting nitric oxide into certain solid tumors is safe and may help shrink tumors that cannot be removed with surgery. It includes adults with measurable, treatment-resistant skin or under-skin (cutaneous or subcutaneous) tumors and checks for side effects and early signs of benefit.
BeershebaAges 18 years+ - NCT05357651RecruitingPhase 1
LB1410 study for advanced lung, colon, and other cancers
This Phase 1 trial tests LB1410, a new cancer treatment, to see if it is safe and may work for people with advanced cancers. It focuses on specific cancer types and requires certain prior treatments and lab test results.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05361174RecruitingPhase 1/Phase 2
Testing an IOV-4001 infusion for advanced melanoma or lung cancer
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Los Angeles, CaliforniaAges 18–70 - NCT05369351RecruitingPhase 2
Mirabegron for brain bleeding soon after symptoms start
This trial studies whether mirabegron can improve safety and outcomes after an intracerebral hemorrhage (a type of brain bleeding). Participants start treatment within 72 hours of symptom onset and are monitored for recovery and side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05371613RecruitingPhase 2/Phase 3
Testing tividenofusp alfa vs idursulfase for MPS II
This trial compares a new treatment (tividenofusp alfa) to the current standard treatment (idursulfase) in children and young adults with MPS II. It’s looking to see which option works better and is safe, especially based on age and whether the disease affects the brain.
Oakland, CaliforniaAges 2–25 - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Los Angeles, CaliforniaAges 12 years+ - NCT05377034RecruitingPhase 2
Y-90 and immunotherapy vs Y-90 plus placebo for liver cancer
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
BeijingAges 21–99 - NCT05378334Recruiting
Test herbal treatment for lung cancer spread to bone
This trial studies whether the herbal medicine HGXJT can improve outcomes and safety for people with non-small cell lung cancer that has spread to the bones. It is designed for a specific lung cancer type (EGFR and ALK wild type) and people who have not had certain immune treatments before.
Guangzhou, GuangdongAges 18–75 - NCT05395689RecruitingPhase 3
Dust mite allergy vaccine for ongoing runny nose and asthma
This Phase 3 study tests Beltavac®, a treatment aimed at dust mite allergies, to see if it can improve persistent nasal allergy symptoms and help people whose asthma is also affected. You may be a good match if you have confirmed dust mite sensitization and ongoing moderate-to-severe symptoms.
Orihuela, AlicanteAges 12–65 - NCT05398809RecruitingPhase 2
Ruxolitinib for hair regrowth in APECED-related alopecia areata
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
Bethesda, MarylandAges 12–75 - NCT05407792Recruiting
Long-term tablets to help bronchiectasis flare-ups
This trial studies whether long-term Staphylococcus albicans tablets can safely reduce bronchiectasis flare-ups and improve symptoms. It may help people with frequent infections/attacks due to bronchiectasis.
Jinan, ShandongAges 18 years+ - NCT05408221RecruitingPhase 2/Phase 3
Liver cancer trial testing Rulonilimab plus Lenvatinib
This Phase 2/3 study tests whether combining rulonilimab with lenvatinib can control unresectable advanced liver cancer (HCC) that cannot be removed by surgery or treated locally. You may be considered if you have not had prior whole-body (systemic) cancer treatments and your organs and blood counts are strong enough.
Beijing, Beijing MunicipalityAges 18–75 - NCT05410925RecruitingPhase 4
Half-dose r-SAK before heart stent procedure for heart attack
This trial tests whether a half-dose medicine called r-SAK given before a primary PCI heart stent procedure improves outcomes and safety in people with a specific type of heart attack. It may help the heart recover better, but it also checks the risk of side effects like bleeding.
Nanjing, JiangsuAges 18–75 - NCT05445063RecruitingPhase 1
iPSC eye-cell transplant for late dry macular degeneration
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
Beijing, Beijing MunicipalityAges 50–75 - NCT05455307Recruiting
Test of a garlic-based ureteral stent for scarred ureter blockage
This study tests whether an Allium-based ureteral stent can improve healing and comfort for people with a scarred ureter (ureteral stricture) that has not responded to prior dilation. You may be asked to accept a stent placed for the long term, depending on your situation.
New Taipei CityAges 18–80 - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.